Pharmaceutical Executive May 3, 2024
Deal includes a number of radioligand therapies targeting solid tumors, such as breast, prostate, and lung cancers.
Novartis announced that it has acquired Mariana Oncology, a biotech specializing in developing radioligand therapies (RLTs) for cancer treatment. According to the company, the acquisition is expected to enhance Novartis’ existing RLT pipeline and add major research capabilities. These programs target breast, prostate, and lung cancers, and features a leading developmental candidate, MC-339, for small cell lung cancer. As per terms of the agreement, Novartis is expected to make an upfront payment of $1 billion, with further potential payments of up to $750 million upon the completion of pre-specified milestones.1
“The acquisition of Mariana Oncology reflects our commitment to radioligand therapy as one...
Today's Sponsors
Today's Sponsor